Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase Ⅱ trial.
Authors: Chunfang Hao, Jing Shi, Yuhua Song, Jie Ma, Hua Yang, Yongsheng Jia, Cuiping Song, Wenjing Meng, Jie Zhang